To,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai - 400001.
Scrip Code: 540737

August 12, 2026

Dear Sir(s)/Ma'am,

Sub: Outcome of the Board Meeting held today i.e. Wednesday, August 12, 2026.

With reference to the captioned subject matter, we would like to inform that the Board of Directors of the Company at its meeting held today i.e. Wednesday, August 12, 2026 has inter-alia considered and approved following:

a) **The Unaudited (Standalone & Consolidated) Financial Results for the quarter ended on June 30, 2026.**

The Board of Directors of the Company has approved the Unaudited (Standalone & Consolidated) Financial Results for the quarter ended on June 30, 2026. The Financial Results along with Auditors Limited Review Reports are enclosed herewith.

b) **Appointment of M/s. M. I. Prajapati & Associates LLP, Cost Accountants, as Cost Auditors for the year 2026– 2027.**

The Board of Directors of the Company, based on the recommendation of the Audit Committee of the Board of Directors, have appointed M/s. M. I. Prajapati & Associates LLP, Cost Accountants, as Cost Auditors for the year 2026– 2027.

c) **Appointment of Mr. Vishal Thawani of M/s. VTSN and Associates LLP, Practicing Company Secretaries, as Scrutinizer for the e-voting process to be conducted at the 31st Annual General Meeting.**

d) **Notice for the 31st Annual General Meeting and the Directors Report together with its Annexures for the year ended on March 31, 2026.**

The details as required under SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026 are annexed herewith.

The Meeting of the Board of Directors of the Company commenced at 05:00 p.m. and concluded at 05:45 p.m.

Kindly take the same on your record.

Thanking you,
Yours Faithfully,
For Shree Ganesh Remedies Limited

ADITYA VIKRAMBHAI PATEL
Digitally signed by ADITYA VIKRAMBHAI PATEL
Date: 2026.08.12 17:56:40 +05'30'

Aditya Patel
Company Secretary

Enclosed: - As stated above

Annexure A

The details required under Regulation 30 of the SEBI Listing Regulations read along with SEBI Master Circular HO/49/14/14(7)2025-CFD-POD2/1/3762 /2026 dated January 30, 2026 are given below.

Sr No	Particulars	Details
1	Reason for change viz. Appointment, re-appointment, resignation, removal, death and otherwise	Appointment of M/s. M. I. Prajapati & Associates LLP, Cost Accountants as Cost Auditors of the Company.
2	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment	Appointment is effective from August 12, 2026 to conduct cost audit for the year 2026–2027.
3	Brief profile (in case of appointment)	M/s. M. I. Prajapati & Associates LLP is a professionally managed consultancy firm based in Ahmedabad, with a legacy dating back to 2012. Reconstituted as a Limited Liability Partnership (LLP) in 2026, the firm brings together nearly 15 years of professional experience and expertise in providing comprehensive business and professional advisory services. The firm offers a wide range of services, including Cost Audit & Cost Consultancy, GST, Income Tax, Company Incorporation & Compliance, Virtual CFO Services, Stock Audit, Fixed Asset Audit, and Management Consultancy. With a team of experienced professionals and a strong focus on practical and compliant solutions, the firm is committed to delivering value-driven, customized services aligned with the specific requirements and objectives of its clients. Driven by a client-centric approach and high professional standards, M/s. M. I. Prajapati & Associates LLP strives to be a trusted professional partner, supporting businesses in achieving sustainable growth, operational efficiency, regulatory compliance, and professional excellence.
4	Disclosure of relationships between directors (in case of appointment of a director).	N.A.

Independent Auditor's Review Report on Unaudited Quarterly Standalone Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,
Shree Ganesh Remedies Limited

1. We have reviewed the accompanying Statement of Unaudited Standalone Financial Results of **Shree Ganesh Remedies Limited** ("the Company") for the quarter ended June 30th ,2026 ("the Statement"), being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Chaudhary Shah & Associates

For, Chaudhary Shah & Associates LLP
Chartered Accountants
FRN: 006212C/W100789

12-08-2026

Shubham Jain
Designated Partner
M.No. 474949
UDIN: 26474949IGEJGN3455

Place: Ahmedabad
Date: 12/08/2026

Independent Auditor's Review Report on Unaudited Quarterly Consolidated Financial Results of Shree Ganesh Remedies Limited pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

To the Board of Directors,
Shree Ganesh Remedies Limited

1. We have reviewed the accompanying Statement of Unaudited Consolidated Financial Results of Shree Ganesh Remedies Limited ("the Holding Company") and its subsidiary (the Holding Company and its subsidiary together referred to as "the Group") for the quarter ended June 30th,2026 ("the Statement"), being submitted by the Holding Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement, which is the responsibility of the Holding Company's Management and approved by the Holding Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standards (Ind AS) 34, "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33(8) of the Listing Regulations, to the extent applicable.

4. The Statement includes the results of the following entity:

Name of the Entity	Relationship
SGRL USA INC	Wholly Owned Subsidiary [with effect from January 8, 2024]

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Ind AS and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of the Listing Regulations, as amended from time to time, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Other matters

6. The accompanying Statement includes the unaudited interim financial results/financial information of 1 (one) subsidiary located outside India, whose unaudited interim financial results/financial information reflect total revenue of ₹ NIL lakhs, total net profit/ (loss) after tax (including due to exchange translation) of ₹ NIL lakhs and total comprehensive income/(loss) (including due to exchange translation) of ₹ (0.01) lakhs, for the quarter ended June 30th,2026 as considered in the Statement. The management of the Holding Company has prepared and certified the unaudited interim financial results/ financial information of this 1 (one) subsidiary in accordance with Ind AS and accounting principles generally accepted in India, and our opinion on the Statement, in so far as it relates to the amounts and disclosures in respect of these subsidiary, is based solely on such financial results/ financial information. In our opinion and according to the information and explanation given to us by the management of the Holding Company, this unaudited interim financial results/ financial information is not material to the Group.

For, Chaudhary Shah & Associates LLP
Chartered Accountants
FRN: 006212C/W100789

12/08/2026

Shubham Jain
Designated Partner
M.No. 474949
UDIN: 26474949YLVHJM2467

Place: Ahmedabad
Date: 12/08/2026

SHREE GANESH REMEDIES LTD
excelling in chemistry

SHREE GANESH **REMEDIES** LIMITED

Manufacturer of API Intermediates & Speciality Chemicals

Standalone Financial Results For the Quarter Ended June 30, 2026

₹ in Lakhs

Sr. No.	Particular	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INCOME				
I	Revenue from Operations	1,436.00	3,319.61	2,466.79	10,928.58
II	Other Income	93.92	102.26	66.17	303.02
III	**Total Income (I +II)**	**1,529.92**	**3,421.87**	**2,532.96**	**11,231.60**
IV	**EXPENSES**				
	Cost of Materials Consumed	839.64	1,103.34	874.05	4,091.90
	Purchases of Stock-in-trade		-	-	-
	Changes in inventories of Finished Goods and Work-in-progress	(630.96)	319.01	(1.27)	95.69
	Employee Benefit Expenses	292.90	287.34	269.83	1,140.04
	Finance Costs	31.89	87.58	94.01	356.19
	Depreciation and Amortisation expense	244.11	279.82	242.01	1,047.30
	Other Expenses	599.22	472.48	594.52	2,098.99
	Total Expenses (IV)	**1,376.80**	**2,549.57**	**2,073.16**	**8,830.11**
V	**Profit/(Loss) before Tax (III-IV)**	**153.12**	**872.30**	**459.80**	**2,401.49**
VI	**Tax Expense**				
	Current Tax	34.58	147.35	101.87	564.83
	Deferred Tax	6.53	97.75	12.99	53.31
	(Excess)/Short provision of tax of earlier years	-	-	-	6.02
	Total Tax Expense (VI)	**41.11**	**245.10**	**114.86**	**624.16**
VII	**Profit/(Loss) for the period after Tax (V-VI)**	**112.01**	**627.20**	**344.94**	**1,777.33**
VIII	**OTHER COMPREHENSIVE INCOME**				
	Items that will not be reclassified to profit or loss				
	Remeasurement Gain/ (Loss) on Defined Measurement Benefit Plans	1.65	13.07	(0.44)	6.60
	Income Tax Relating to above	(0.42)	(3.29)	0.11	(1.66)
	Total Other Comprehensive Income for the year (VIII)	**1.23**	**9.78**	**(0.33)**	**4.94**
IX	**Total Comprehensive Income for the year (VII+VIII)**	**113.24**	**636.98**	**344.62**	**1,782.27**
X	**Earning Per Share of ₹ 10 Par Value**				
	Paid - up Equity Share Capital (Face Value ₹ 10 each)	1,283.76	1,283.76	1,283.76	1,283.76
	Basic (In ₹ per share)	0.87	4.88	2.69	13.84
	Diluted (In ₹ per share)	0.87	4.88	2.69	13.84

For Shree Ganesh Remedies Limited

SHREE GANESH REMEDIES LTD ANKLESHWAR SGR

Chandulal Manubhai Kothia
DIN: 00652806
Managing Director
Place: Ankleshwar
Date: 12-08-2026

For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789

12-08-2026

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad
Date: 12-08-2026

Chaudhary Shah & Associates

Consolidated Financial Results For the Quarter ended June 30, 2026

₹ in Lakhs

Sr. No.	Particular	Quarter ended			Year ended
		June 30, 2026	March 31, 2026	June 30, 2025	March 31, 2026
		(Unaudited)	(Audited)	(Unaudited)	(Audited)
	INCOME				
I	Revenue from Operations	1,436.00	3,319.61	2,466.79	10,928.58
II	Other Income	93.92	102.26	66.17	303.02
III	**Total Income (I +II)**	**1,529.92**	**3,421.87**	**2,532.96**	**11,231.60**
IV	**EXPENSES**				
	Cost of Materials Consumed	839.64	1,103.34	874.05	4,091.90
	Purchases of Stock-in-trade	-	-	-	-
	Changes in inventories of Finished Goods and Work-in-progress	(630.96)	319.01	(1.27)	95.69
	Employee Benefit Expenses	292.90	287.34	269.83	1,140.04
	Finance Costs	31.89	87.58	94.01	356.19
	Depreciation and Amortisation expense	244.11	279.82	242.01	1,047.30
	Other Expenses	599.22	472.48	594.52	2,098.99
	Total Expenses (IV)	1,376.80	**2,549.57**	**2,073.16**	**8,830.11**
V	**Profit/(Loss) before Tax (III-IV)**	153.12	**872.30**	**459.80**	**2,401.49**
VI	**Tax Expense**				
	Current Tax	34.58	147.74	102.31	566.17
	Deferred Tax	6.53	97.75	12.99	53.31
	(Excess)/Short provision of tax of earlier years	-	-	-	6.02
	Total Tax Expense (VI)	**41.11**	**245.49**	**115.29**	**625.50**
VII	**Profit/(Loss) for the period after Tax (V-VI)**	**112.01**	**626.81**	**344.51**	**1,775.99**
VIII	**OTHER COMPREHENSIVE INCOME**				
	Items that will not be reclassified to profit or loss				
	Exchange Differences in translating the financial statements of foreign operations	(0.01)	0.20	(0.02)	0.36
	Remeasurement Gain/ (Loss) on Defined Measurement Benefit Plans	1.65	13.07	(0.44)	6.60
	Income Tax Relating to above	(0.41)	(3.29)	0.11	(1.66)
	Total Other Comprehensive Income for the year (VIII)	**1.23**	**9.98**	**(0.35)**	**5.30**
IX	**Total Comprehensive Income for the year (VII+VIII)**	**113.24**	**636.79**	**344.16**	**1,781.29**
X	**Earning Per Share of ₹ 10 Par Value**				
	Paid - up Equity Share Capital (Face Value ₹ 10 each)	1,283.76	1,283.76	1,283.76	1,283.76
	Basic (In ₹ per share)	0.87	4.88	2.68	13.83
	Diluted (In ₹ per share)	0.87	4.88	2.68	13.83

For Shree Ganesh Remedies Limited

Chandulal Manubhai Kothia
DIN: 00652806
Managing Director
Place: Ankleshwar
Date: 12-08-2026

For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789

12-08-2026

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad
Date: 12-08-2026

Notes to Financial Results for the Quarter Ended June 30, 2026

1 The above results which are published have been reviewed and recommended by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on August 12, 2026. The Financial results of the Company have been prepared in accordance with the Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and the other accounting principles generally accepted in India.

2 The Company is primarily engaged in the business of Bulk Drug Intermediates, which constitute a single reportable segment in accordance with Ind AS 108 - "Segment Reporting".

3 Earnings per share (EPS) is calculated on the weighted average of share capital outstanding during the year as per Ind AS 33 on "Earnings Per Share". EPS for the Quarter ended June 30, 2026, March 31, 2026, June 30, 2025 are not annualised.

4 Kamalam Foundation which is incorporated under Section 8 of the Companies Act, 2013 is prohibited to give any right over their profits to its members and accordingly, no share in surplus of Kamalam Foundation is considered to be that of the Company for the purpose of preparation and presentation of consolidated financial results/financial statements/financial information.

5 Previous year's / period's figures are regrouped wherever necessary to make them comparable with current year's / period's grouping.

For Shree Ganesh Remedies Limited

SHREE GANESH REMEDIES LTD. SGR ANKLESHWAR

Chandulal Manubhai Kothia
DIN: 00652806
Managing Director
Place: Ankleshwar
Date: 12-08-2026

For Chaudhary Shah and Associates LLP
Chartered Accountants, FRN:006212C/W100789

12-08-2026

Shubham Jain
Designated Partner
M.No. 474949
Place: Ahmedabad
Date: 12-08-2026

Chaudhary Shah & Associates